Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran

  • Zahra Aajami Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Abbas Kebriaeezadeh Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Shekoufeh Nikfar Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran and Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran
Keywords: Alzheimer’s Disease, Cost Analysis, Direct Cost, Indirect Cost

Abstract

Background: Alzheimer’s disease (AD) affects a large number of adults annually all around the world. The monetary cost of this disorder is huge. This study aims to estimate the cost of AD in Iran by considering stages of disease.

Methods: A cross-sectional study was designed from July to December 2017 on 300 AD cases who referred to the Iran Alzheimer’s Association, Tehran, Iran. To calculate costs at different stages of disease, patients were assigned into three groups, based on the Mini-Mental State Exam (MMSE) score. A list of medicines’ prices and health care service costs were prepared. Health care services’ cost was acquired from the book of “Relative value units of health care services in Iran” and the price of medicines was extracted from "Iran’s medicine triple prices list". Patients’ medical records and face to face interview with their caregivers were used for data collection. The perspective of present research was societal.

Results: Annually, per person cost of AD in mild, moderate, and severe stages of disease were 434 United States dollars (USD), 1313 USD, and 2480 USD, respectively. Direct non-medical costs (DNMC) had the greatest share of total costs (near half of the whole costs) including 263 USD, 641 USD, and 1257 USD for mild, moderate, and severe stages, respectively.

Conclusion: The cost of AD in Iran is lower than the average cost of dementia in upper middle-income countries. In all stages, the biggest part of the cost is associated with patient care and nursing services because patients suffering from AD usually require specialized cares.

References

1. Alzheimer's Disease International. World Alzheimer Report 2014: Dementia and Risk Reduction [Online]. [cited 2014]; Available from: URL: https://www.alz.co.uk/research/world-report-2014
2. Alzheimer's Disease Education & Referral Center. Alzheimer's disease [Online]. [cited 2011]; Available from: URL: http://www.nia.nih.gov/Alzheimers/ Publications /adfact.htm
3. Jost BC, Grossberg GT. The natural history of Alzheimer's disease: A brain bank study. J Am Geriatr Soc 1995; 43(11): 1248-55.
4. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80(19): 1778-83.
5. Prince M, Bryce R, Ferri C. World Alzheimer report 2011: The benefits of early diagnosis and intervention. London, UK: Alzheimer's Disease International; 2011.
6. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3(3): 186-91.
7. Zohari S, Khatouni S, Abed Saeidi ZH, Alavi Majd H, Yaghmaei F. Problems of main caregivers of Alzheimer patients referring to Alzheimer association in Tehran. Faculty of Nursing of Midwifery Quarterly 2006; 16(53): 64-72. [In Persian].
8. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001; 15(4): 169-73.
9. Gholamzadeh S, Heshmati B, Mani A, Petramfar P, Baghery Z. The prevalence of Alzheimer's disease; its risk and protective factors among the elderly population in Iran. Shiraz E-Med J 2017; 18(9): e57576.
10. The National Institute for Health and Care Excellence. Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease [Online]. [cited 2018]; Available from: URL: https://www.nice.org.uk/guidance/ta217
11. Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13(1): 1-7.
12. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 368(14): 1326-34.
13. Luengo-Fernandez R, Leal J, Gray AM. Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis 2011; 27(1): 187-96.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189-98.
15. Foroughan M, Jafari Z, Shirin Bayan P, Ghaem Magham Faraahani Z, Rahgozar M. Validation of mini-mental state examination (MMSE) in the elderly population of Tehran. Adv Cogn Sci 2008; 10(2): 29-37. [In Persian].
16. Ganjali M, Baghfalaki T. Bayesian analysis of unemploymentduration data in the presence of right andinterval censoring. Journal of Reliability and Statistical Studies 2012; 5(1): 17-32. [In Persian].
17. Central Bank of the Islamic Republic of Iran. The Rate Currency Iran [Online]. [cited 2018]; Available from: URL:
https://www.cbi.ir/exrates/rates_fa.aspx
18. Statistical Center of Iran. Annual income of an Iranian urban household [Online]. [cited 2018 Nov 17]; Available from: URL: https://www.amar.org.ir/Portals/0/PropertyAgent/461/Files/9836/28011111z11396.xlsx
19. Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: Cost-effectiveness analysis in France. Eur J Health Econ 2014; 15(8): 791-800.
20. Suh GH. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea. Value Health 2009; 12(Suppl 3): S49-S54.
Published
2019-02-16
How to Cite
1.
Aajami Z, Kebriaeezadeh A, Nikfar S. Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran. Iran J Neurol. 18(1):7-12.
Section
Original Article(s)